Michael J. Fox Foundation for Parkinson's Research

The biopharma sector has transformed countless lives with innovative therapies, yet an estimated 85-90% of rare diseases lack any approved treatment. The economics of developing new medicines for some

The first half of July brought an explosion of venture capital fireworks with several $100m-plus financings for biopharmaceutical companies, but the pace of mega-round announcements has fizzled out in

Biopharmaceutical venture capital fundraising is on the rise in 2024, boosted in part by surging numbers of $100m-plus mega-rounds, including a pair of large financings that ended June and started Jul

Two new venture capital funds based outside of the US together offer $365m for life science start-ups, including Amplitude Ventures’ second fund and XGEN Venture’s inaugural fund. Montreal-based Ampli